Clinical Trial Update: Addition of Opaganib to Androgen Antagonists in Patients With mCRPC [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating the addition of opaganib to androgen antagonists in patients with metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Opaganib (opaganib)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-09-25